Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety.

De Nayer A, Geerts S, Ruelens L, Schittecatte M, De Bleeker E, Van Eeckhoutte I, Evrard JL, Linkowski P, Fossion P, Leyman S, Mignon A.

Int J Neuropsychopharmacol. 2002 Jun;5(2):115-20.

PMID:
12135535
3.

A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients.

Diaz-Martinez A, Benassinni O, Ontiveros A, Gonzalez S, Salin R, Basquedano G, Martinez RA.

Clin Ther. 1998 May-Jun;20(3):467-76.

PMID:
9663362
4.

Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia.

Tzanakaki M, Guazzelli M, Nimatoudis I, Zissis NP, Smeraldi E, Rizzo F.

Int Clin Psychopharmacol. 2000 Jan;15(1):29-34. Erratum in: Int Clin Psychopharmacol 2000 Mar;15(2):120.

PMID:
10836283
5.
6.
7.
8.

Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.

Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D.

Depress Anxiety. 2002;16(1):4-13.

PMID:
12203668
9.

A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients.

Dierick M, Ravizza L, Realini R, Martin A.

Prog Neuropsychopharmacol Biol Psychiatry. 1996 Jan;20(1):57-71.

PMID:
8861177
10.

The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia.

Ballús C, Quiros G, De Flores T, de la Torre J, Palao D, Rojo L, Gutiérrez M, Casais L, Riesgo Y.

Int Clin Psychopharmacol. 2000 Jan;15(1):43-8.

PMID:
10836286
11.

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E.

JAMA. 2000 Jun 21;283(23):3082-8.

PMID:
10865302
12.
13.

A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients.

Nemeroff CB, Thase ME; EPIC 014 Study Group.

J Psychiatr Res. 2007 Apr-Jun;41(3-4):351-9. Epub 2005 Sep 12.

PMID:
16165158
14.

Venlafaxine versus fluoxetine in the treatment of atypical anorectic outpatients: a preliminary study.

Ricca V, Mannucci E, Paionni A, Di Bernardo M, Cellini M, Cabras PL, Rotella CM.

Eat Weight Disord. 1999 Mar;4(1):10-4.

PMID:
10728173
15.

The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases.

Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Dunlop BW, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen R, Yan B, Ahmed S, Schmidt M, Ninan PT.

Biol Psychiatry. 2007 Dec 15;62(12):1371-9. Epub 2007 Sep 7. Erratum in: Biol Psychiatry. 2012 Feb 15;71(4):387. Biol Psychiatry. 2008 Apr;63(7):721.

PMID:
17825800
16.

Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features.

Guelfi JD, Ansseau M, Timmerman L, Kørsgaard S; Mirtazapine-Venlafaxine Study Group.

J Clin Psychopharmacol. 2001 Aug;21(4):425-31.

PMID:
11476127
18.

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

Rickels K, Pollack MH, Sheehan DV, Haskins JT.

Am J Psychiatry. 2000 Jun;157(6):968-74.

PMID:
10831478
19.
20.

Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients.

Feighner JP, Entsuah AR, McPherson MK.

J Affect Disord. 1998 Jan;47(1-3):55-62.

PMID:
9476744

Supplemental Content

Support Center